4D Molecular Company Insiders

4D Molecular Management Team Effectiveness

The company has return on total asset (ROA) of (0.1686) % which means that it has lost $0.1686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2406) %, meaning that it created substantial loss on money invested by shareholders. 4D Molecular's management efficiency ratios could be used to measure how well 4D Molecular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, 4D Molecular's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 800.4 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 14.9 M in 2024. Common Stock Shares Outstanding is likely to drop to about 28.2 M in 2024. Net Loss is likely to gain to about (91.9 M) in 2024

4D Molecular Workforce Comparison

4D Molecular Insider Trading History

4D Molecular Notable Stakeholders

The success or failure of an entity such as 4D Molecular Therapeutics often depends on how effective the management is. 4D Molecular management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of FDMT management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the FDMT management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in 4D Molecular's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of 4D Molecular Therapeutics. Check 4D Molecular's Beneish M Score to see the likelihood of 4D Molecular's management manipulating its earnings.

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.